☆ 4.8 Article

SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern

ELIFE (2022)

Related references

Note: Only part of the references are listed.

Letter Medicine, General & Internal

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose

Constanze Kuhlmann et al.

LANCET (2022)

Add to Collection

Article Multidisciplinary Sciences

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Juan Manuel Carreno et al.

Summary: The Omicron variant of SARS-CoV-2, first identified in South Africa and Botswana in November 2021, has rapidly spread globally with high transmissibility. It has an unprecedented number of mutations in its spike gene, leading to immune escape and reduced vaccine efficacy. The neutralizing and binding activity against Omicron varies among individuals with different vaccination and infection histories.

NATURE (2022)

Add to Collection

Article Immunology

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

Jingwen Ai et al.

Summary: This study explored the immunogenicity of different vaccination strategies against the Omicron variant of SARS-CoV-2. The results showed that the Omicron variant has a high immune escape ability compared to other variants, but heterologous protein subunit vaccines and homologous inactivated vaccine boosters can improve neutralization against Omicron.

EMERGING MICROBES & INFECTIONS (2022)

Add to Collection

Article Immunology

Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters

Rebecca L. Brocato et al.

Summary: Global efforts to combat the COVID-19 pandemic have led to the development of numerous candidate vaccines in different stages of research and development. A DNA vaccine targeting the spike protein of SARS-CoV-2 demonstrated the ability to generate neutralizing antibodies and provide protection in hamster models, showing potential for further preclinical studies.

NPJ VACCINES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al.

Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.

CELL (2021)

Add to Collection

Article Microbiology

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Xiaoying Shen et al.

Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.

CELL HOST & MICROBE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

SARS-CoV-2 variants and ending the COVID-19 pandemic

Arnaud Fontanet et al.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice

Inga Szurgot et al.

Summary: The study compared the immunogenicity of two alphavirus-based DNA-launched self-replicating (DREP) vaccine candidates encoding different forms of the SARS-CoV-2 spike protein. It was found that the unmodified spike vaccine was more effective in inducing high levels of neutralizing antibodies in mice. Additionally, both vaccine candidates were able to prime immune responses against SARS-CoV-2 and could be enhanced with a heterologous spike protein immunization.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model

Sreelekshmy Mohandas et al.

Summary: The study demonstrated that the BBV152A and BBV152B vaccine candidates induced quick and robust immune responses, providing protection to Syrian hamsters from lung pathology after SARS-CoV-2 infection.

ISCIENCE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Inactivation of SARS-CoV-2 Laboratory Specimens

Elaine Haddock et al.

Summary: Diagnostic and research laboratories face a high burden of providing reliable inactivation for biological specimens during the COVID-19 pandemic to ensure safe downstream processing. Safety data regarding commonly used chemical and physical inactivation procedures against SARS-CoV-2 effectiveness is provided.

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Xiaoying Shen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Microbiology

Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model

Drishya Kurup et al.

Summary: The study developed an inactivated rabies virus vectored vaccine platform, resulting in a vaccine against SARS-CoV-2 named CORAVAX. CORAVAX demonstrated effectiveness in preventing viral replication and lung disease in hamster models, showing potential for robust immune responses in humans.

PLOS PATHOGENS (2021)

Add to Collection

Article Immunology

Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease

Joan E. M. van der Lubbe et al.

Summary: This study investigated the immunogenicity, protective efficacy, and potential for vaccine-associated enhanced respiratory disease (VAERD) mediated by Ad26.COV2.S in a Syrian hamster challenge model with the G614 spike SARS-CoV-2 variant. Results showed that higher vaccine doses elicited substantial neutralizing antibodies titers and provided complete protection against lung infection and pneumonia in over 80% of Syrian hamsters inoculated with SARS-CoV-2.

NPJ VACCINES (2021)

Add to Collection

Article Immunology

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Susanne Rauch et al.

Summary: mRNA technologies have shown clinical efficacy against COVID-19, with the CVnCoV vaccine demonstrating strong immune responses and protection against SARS-CoV-2 in preclinical studies. Overall, CVnCoV represents a potent and safe candidate for a COVID-19 vaccine.

NPJ VACCINES (2021)

Add to Collection

Review Microbiology

The success of SARS-CoV-2 vaccines and challenges ahead

Kanta Subbarao

Summary: The development of effective SARS-CoV-2 vaccines is facing challenges in preventing asymptomatic and mild infections, potential updates required due to the emergence of variants with mutations, and concerns about the longevity of vaccine-induced immunity. Coordination in global surveillance, updating vaccines, and potential re-vaccination may be necessary to address these challenges.

CELL HOST & MICROBE (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Aziz Sheikh et al.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

Add to Collection

Letter Medicine, General & Internal

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Venkata-Viswanadh Edara et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cell Biology

A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters

Yangtao Wu et al.

Summary: This study developed a protein subunit vaccine consisting of spike ectodomain protein and a nitrogen bisphosphonate-modified zinc-aluminum hybrid adjuvant, which showed higher neutralizing antibody titers in animal models and induced T cell responses. The vaccine provided protection against SARS-CoV-2 challenge and reduced virus transmission among vaccinated and unvaccinated animals.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021

Catherine M. Brown et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Immunology

Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant

Claude Kwe Yinda et al.

Summary: The study demonstrates that aerosol exposure to SARS-CoV-2 is a more efficient route of infection compared to fomite exposure. Previous infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but does prevent disease and onward transmission.

EMERGING MICROBES & INFECTIONS (2021)

Add to Collection

Article Cell Biology

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

Ahmed O. Hassan et al.

Summary: The study demonstrates the immunogenicity and protective efficacy of an intranasally administered vaccine in non-human primates, showing that it induces neutralizing antibodies and T cell responses, effectively limiting or preventing infection of SARS-CoV-2 in the respiratory tract.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Immunology

A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters

Bao-Zhong Zhang et al.

Summary: The S-ID vaccine candidate induced better neutralizing antibody response and showed reduced body weight loss, lung viral load, and histopathological changes in hamsters, suggesting its potential as an effective COVID-19 vaccine.

EMERGING MICROBES & INFECTIONS (2021)

Add to Collection

Article Infectious Diseases

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Victor M. Corman et al.

EUROSURVEILLANCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Noe B. Mercado et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Neeltje van Doremalen et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Kizzmekia S. Corbett et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Cell Biology

An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates

Jesse H. Erasmus et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

Paul F. McKay et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Multidisciplinary Sciences

A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine

Cindy Hoerner et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Article Immunology

Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection

Kyle Rosenke et al.

EMERGING MICROBES & INFECTIONS (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.